These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 28842990)

  • 1. Migraine Prophylaxis and Acute Treatment Patterns Among Commercially Insured Patients in the United States.
    Woolley JM; Bonafede MM; Maiese BA; Lenz RA
    Headache; 2017 Oct; 57(9):1399-1408. PubMed ID: 28842990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis.
    Hepp Z; Dodick DW; Varon SF; Chia J; Matthew N; Gillard P; Hansen RN; Devine EB
    Cephalalgia; 2017 Apr; 37(5):470-485. PubMed ID: 27837173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and determinants of migraine prophylactic medication in the Netherlands.
    Rahimtoola H; Buurma H; Tijssen CC; Leufkens HG; Egberts AC
    Eur J Clin Pharmacol; 2002 May; 58(2):149-55. PubMed ID: 12012149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence with migraine prophylactic treatment and acute migraine medication utilization in the managed care setting.
    Yaldo AZ; Wertz DA; Rupnow MF; Quimbo RM
    Clin Ther; 2008 Dec; 30(12):2452-60. PubMed ID: 19167603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
    Buse DC; Serrano D; Reed ML; Kori SH; Cunanan CM; Adams AM; Lipton RB
    Headache; 2015 Jun; 55(6):825-39. PubMed ID: 25881857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of switching acute treatment on disability in migraine patients using triptans.
    Serrano D; Buse DC; Kori SH; Papapetropoulos S; Cunanan CM; Manack AN; Reed ML; Lipton RB
    Headache; 2013 Oct; 53(9):1415-29. PubMed ID: 23808937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence with migraine prophylaxis in clinical practice.
    Berger A; Bloudek LM; Varon SF; Oster G
    Pain Pract; 2012 Sep; 12(7):541-9. PubMed ID: 22300068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study.
    Kawata AK; Shah N; Poon JL; Shaffer S; Sapra S; Wilcox TK; Shah S; Tepper SJ; Dodick DW; Lipton RB
    Headache; 2021 Mar; 61(3):438-454. PubMed ID: 33594686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erenumab patient characteristics, medication adherence, and treatment patterns in the United States.
    Hines DM; Shah S; Multani JK; Wade RL; Buse DC; Bensink M
    Headache; 2021 Apr; 61(4):590-602. PubMed ID: 33594672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health care resource utilization following initiation of a triptan: a retrospective claims analysis.
    Messali A; Owens G; Bloudek L; Kori S; Cole A; Chia J
    J Manag Care Spec Pharm; 2014 Apr; 20(4):368-75. PubMed ID: 24684641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA.
    Runken MC; Goodwin B; Shah M; Eaddy M; D'Souza A; Bowers B; Bell CF
    Appl Health Econ Health Policy; 2015 Feb; 13(1):109-20. PubMed ID: 25294555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors Associated with Direct Health Care Costs Among Patients with Migraine.
    Bonafede M; Cai Q; Cappell K; Kim G; Sapra SJ; Shah N; Widnell K; Winner P; Desai P
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1169-1176. PubMed ID: 29083975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term treatment patterns of prophylactic and acute migraine medications and incidence of opioid-related adverse events in patients with migraine.
    Bonafede M; Wilson K; Xue F
    Cephalalgia; 2019 Aug; 39(9):1086-1098. PubMed ID: 30818974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resource use associated with topiramate in migraine prophylaxis.
    Feliu AL; Rupnow MF; Blount A; Boccuzzi SJ; Vermilyea J
    Am J Health Syst Pharm; 2007 Jul; 64(14):1483-91. PubMed ID: 17617498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment patterns and characteristics of patients with migraine in Japan: A retrospective analysis of health insurance claims data.
    Meyers JL; Davis KL; Lenz RA; Sakai F; Xue F
    Cephalalgia; 2019 Oct; 39(12):1518-1534. PubMed ID: 31154807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Migraine prophylactic medication usage patterns in The Netherlands.
    Rahimtoola H; Buurma H; Tijssen CC; Leufkens HG; Egberts AC
    Cephalalgia; 2003 May; 23(4):293-301. PubMed ID: 12716348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence and switching patterns of migraine prophylactic medications in Canada: A retrospective claims analysis comparing adherence and evaluating the economic burden of illness.
    Ojo A; Zhang S; Bleibdrey N; Zimskind D; Keshvani N; Chalmers R
    J Pharm Pharm Sci; 2023; 25():402-417. PubMed ID: 36623477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute treatment patterns in patients with migraine newly initiating a triptan.
    Lipton RB; Marcus SC; Shewale AR; Dodick DW; Viswanathan HN; Doshi JA
    Cephalalgia; 2020 Apr; 40(5):437-447. PubMed ID: 32138526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment patterns of galcanezumab versus standard of care preventive migraine medications over 24 months: a US retrospective claims study.
    Varnado OJ; Vu M; Buysman EK; Kim G; Allenback G; Hoyt M; Trenz H; Cao F; Viktrup L
    Curr Med Res Opin; 2024 Apr; 40(4):635-646. PubMed ID: 38334320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting initiation of preventive migraine medications: exploratory study in a large U.S. medical claims database.
    Ford JH; Schroeder K; Buse DC; Joshi S; Gelwicks S; Foster SA; Aurora SK
    Curr Med Res Opin; 2020 Jan; 36(1):51-61. PubMed ID: 31422701
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.